Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN). Integration requires two metal-dependent reactions, 3′ end processing and strand transfer. Compounds that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication. To characterize the molecular basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs. These studies focused on investigating the role of the conserved carboxylate and metal binding. We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor. Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg 2+ . The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical metal cofactor(s). These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The INSTI pharmacophore consists of a metal chelating core - generally a co-planar triad of oxygen atoms - and a halobenzyl side chain (Fig. 5A, shown in red and blue, respectively)156.”
From Structure and function of retroviral integrase (2022) · cites this paper as [156]
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Self-citationDNA Polymerases: Structural Diversity and Common Mechanisms
Steitz, T. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17395 · Cited by 848
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
Davies, J. F., Hostomska, Z., Hostomsky, Z., Jordan, S. R., & Matthews, D. A. (1991) · Science · doi:10.1126/science.1707186 · Cited by 570
Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., & Davies, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13040 · Cited by 496
Three-Dimensional Structure of the Tn 5 Synaptic Complex Transposition Intermediate
Davies, D. R., Goryshin, I. Y., Reznikoff, W. S., & Rayment, I. (2000) · Science · doi:10.1126/science.289.5476.77 · Cited by 427
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410
Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium
Goldgur, Y., Dyda, F., Hickman, A. B., Jenkins, T. M., Craigie, R., & Davies, D. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9150 · Cited by 380
Sherman, P. A., & Fyfe, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5119 · Cited by 334
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Self-citation
Research works printed but not linked: 1
- P O Brown Retroviruses, eds J M Coffin, S H Hughes, H E Varmus (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 161–203 (1997).
Cited by
Items 101–200 of 443
Crosby, D. C., Lei, X., Gibbs, C. G., McDougall, B. R., Robinson, W. E., & Reinecke, M. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1010594 · Cited by 53
Raltegravir: molecular basis of its mechanism of action
Mouscadet, J. F., & Tchertanov, L. (2009) · European journal of medical research · doi:10.1186/2047-783x-14-s3-5 · Cited by 71
“Such groups are present in all effective IN inhibitors, including raltegravir [40].”
BackgroundA High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPase
Seamon, K. J., & Stivers, J. T. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115575150 · Cited by 55
“We note that the Zn dependence of Ceph C inhibition is evocative of the diketo acid metal chelate inhibitors of HIV integrase.(29) These potent inhibitors coordinate divalent cations and are significantly more inhibitory in their metal-complexed form.”
BackgroundKessl, J. J., Li, M., Ignatov, M., Shkriabai, N., Eidahl, J. O., Feng, L., Musier-Forsyth, K., Craigie, R., & Kvaratskhelia, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr581 · Cited by 52
“The inhibitor effectively impairs binding of the target DNA to the SSC and prevents formation of the strand transfer complex (18,58).”
BackgroundRaltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium
Nguyen, B., Isaacs, R., Teppler, H., Leavitt, R. Y., Sklar, P. A., Iwamoto, M., Wenning, L. A., Miller, M. D., Chen, J., Kemp, R. K., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05972.x · Cited by 55
Self-citationIntegrase strand transfer inhibitor-associated diabetes mellitus: A case report
Fong, P., Flynn, D. M., Evans, C. D., & Korthuis, P. T. (2016) · International Journal of STD & AIDS · doi:10.1177/0956462416675107 · Cited by 52
“The INSTIs not only bind specifically to the catalytic DDE motif to disrupt IN activity, but also chelate metal cations Mg2þ and Mn2þ to prevent the catalysis of integration.(4,5) We hypothesize that INSTIs mechanistically induce hyperglycemia and DM through chelation of the essential metal cation, Mg2þ.”
BackgroundGleenberg, I. O., Avidan, O., Goldgur, Y., Herschhorn, A., & Hizi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414679200 · Cited by 55
Hombrouck, A., Voet, A., Van Remoortel, B., Desadeleer, C., De Maeyer, M., Debyser, Z., & Witvrouw, M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00911-07 · Cited by 51
“It has been proposed that binding of DKAs involves chelating the critical divalent metal ions in the IN catalytic core, resulting in subsequent sequestration of the metal cofactor, which acts normally as a coordination bridge between the IN DDE motif, the viral cDNA donor, and the host DNA (9, 13).”
BackgroundDiketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality
Zhao, X. Z., Maddali, K., Marchand, C., Pommier, Y. G., & Burke, T. R. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.008 · Cited by 50
Conformationally restrained carbazolone-containing α,γ-diketo acids as inhibitors of HIV integrase
Li, X., & Vince, R. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.013 · Cited by 50
Zhao, Z., McKee, C. J., Kessl, J. J., Santos, W. L., Daigle, J. E., Engelman, A., Verdine, G., & Kvaratskhelia, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705241200 · Cited by 49
Doxycycline has distinct apicoplast-specific mechanisms of antimalarial activity
Okada, M., Guo, P., Nalder, S.-A., & Sigala, P. A. (2020) · eLife · doi:10.7554/elife.60246 · Cited by 48
Santo, R. D., Costi, R., Roux, A., Miele, G., Crucitti, G. C., Iacovo, A., Rosi, F., Lavecchia, A., Marinelli, L., Giovanni, C. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001422 · Cited by 51
Stagliano, K. W., Emadi, A., Lu, Z., Malinakova, H. C., Twenter, B. M., Yu, M. L., Holland, L. E., Rom, A. M., Harwood, J. S., Amin, R., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.04.034 · Cited by 48
Recent progress in antiretrovirals – lessons from resistance
Adamson, C. S., & Freed, E. O. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.003 · Cited by 50
An Efficient and Highly Diastereoselective Synthesis of GSK1265744, a Potent HIV Integrase Inhibitor
Wang, H., Kowalski, M. D., Lakdawala, A. S., Vogt, F. G., & Wu, L. (2015) · Organic Letters · doi:10.1021/ol503580t · Cited by 47
Al-Mijalli, S. H., Mrabti, H. N., Ouassou, H., Flouchi, R., Abdallah, E. M., Sheikh, R. A., Alshahrani, M. M., Awadh, A. A. A., Harhar, H., Omari, N. E., et al. (2022) · Life · doi:10.3390/life12111876 · Cited by 54
Pandey, K. K., Bera, S., Zahm, J., Vora, A., Stillmock, K., Hazuda, D., & Grandgenett, D. P. (2007) · Journal of Virology · doi:10.1128/jvi.02863-06 · Cited by 45
“purportedly stabilize the IN-DNA complex (19, 30) by captur* Corresponding author.”
BackgroundInfluentialSelf-citationPostexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors
Dobard, C., Sharma, S., Parikh, U. M., West, R., Taylor, A., Martin, A. M., Pau, C., Hanson, D. L., Lipscomb, J. T., Smith, J. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007701 · Cited by 49
Self-citationRecent Advances in Computer-Aided Drug Design as Applied to Anti-Influenza Drug Discovery
Mallipeddi, P. L., Kumar, G., White, S. W., & Webb, T. R. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929153812 · Cited by 47
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
Bar-Magen, T., Sloan, R. D., Faltenbacher, V. H., Donahue, D. A., Kuhl, B. D., Oliveira, M., Xu, H., & Wainberg, M. A. (2009) · Retrovirology · doi:10.1186/1742-4690-6-103 · Cited by 47
“for each of subtype B versus C enzymes with each of RAL, EVG and MK-2048 in a microtiter plate system [24] (Table 2). Consistent with previous observations, IC50 values were lower when these reactions were performed with MgCl2 than with MnCl2 [2, 24 ].”
MethodInfluentialCorona, A., Leva, F. S. D., Rigogliuso, G., Pescatori, L., Madia, V. N., Subra, F., Delelis, O., Esposito, F., Cadeddu, M., Costi, R., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.09.008 · Cited by 45
Tchertanov, L., & Mouscadet, J. F. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061375j · Cited by 46
Efficient 3D Database Screening for Novel HIV-1 IN Inhibitors
Barreca, M. L., Rao, A., Luca, L. D., Zappalà, M., Gurnari, C., Monforte, P., Clercq, E. D., Maele, B. V., Debyser, Z., Witvrouw, M., et al. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034296e · Cited by 44
Xu, Y., Zeng, C., Jiao, Z.-G., Hu, L.-M., & Zhong, R. (2009) · Molecules · doi:10.3390/molecules14020868 · Cited by 43
“The former serves as the pharmaphore and is proposed to sequester the divalent cofactors (Mg) in the IN active site and thus block access of a host DNA to the integrase [13,14].”
BackgroundShkriabai, N., Patil, S. S., Hess, S., Budihas, S. R., Craigie, R., Burke, T. R., Le Grice, S. F. J., & Kvaratskhelia, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400873101 · Cited by 43
Langley, D. R., Samanta, H. K., Lin, Z., Walker, M. A., Krystal, M. R., & Dicker, I. B. (2008) · Biochemistry · doi:10.1021/bi801372d · Cited by 42
HIV-1 IN Strand Transfer Chelating Inhibitors: A Focus on Metal Binding
Bacchi, A., Carcelli, M., Compari, C., Fisicaro, E., Pala, N., Rispoli, G., Rogolino, D., Sanchez, T. W., Sechi, M., & Neamati, N. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100343x · Cited by 42
Novel furocoumarins as potential HIV-1 integrase inhibitors
Olomola, T. O., Mosebi, S., Klein, R., Traut-Johnstone, T., Coates, J., Hewer, R., & Kaye, P. T. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.07.008 · Cited by 43
Recent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase
Choi, E., Mallareddy, J. R., Lu, D., & Kolluru, S. (2018) · Future Science OA · doi:10.4155/fsoa-2018-0060 · Cited by 51
Brigo, A., Lee, K. W., Fogolari, F., Mustata, G. I., & Briggs, J. M. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20447 · Cited by 44
“Conformation 7 (Table I) led to only 1 complex that allowed the inhibitor to interact with the Mg(2) ion through its keto–enolic motif; this type of complex is in agreement with the hypothesis that IN inhibition occurs by means of divalent cofactor chelation.(38,41,42) Conformation 9 (Table I) is the one that showed t…”
BackgroundJohnson, A. A., Marchand, C., Patil, S. S., Costi, R., Santo, R. D., Burke, T. R., & Pommier, Y. G. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.030817 · Cited by 42
“The most ST-selective inhibitors include the DKA derivative L-708,906 (Hazuda et al., 2000, 2004b; Grobler et al., 2002; Marchand et al., 2002, 2003; Pais et al., 2002), the naphthy-”
BackgroundInfluentialDas, K., Balzarini, J. M., Miller, M. T., Maguire, A. R., DeStefano, J. J., & Arnold, E. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00187 · Cited by 44
“A systematic elaboration from the metal-chelating diketo acid moiety helped gain specificity and efficacy even in the absence of any three-dimensional structural information 47 .”
Kinetic study of the HIV−1 DNA 3′‐end processing: Single‐turnover property of integrase
Smolov, M., Gottikh, M., Ташлицкий, В. Н., Korolev, S. V., Demidyuk, I. V., Brochon, J., Mouscadet, J. F., & Deprez, E. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05139.x · Cited by 43
Hartman, T. L., & Buckheit, R. W. (2012) · Molecular Biology International · doi:10.1155/2012/401965 · Cited by 41
“For optimal integrase inhibition, the pharmacophore requires a regionspecific (N-1) diketoacid of specific length [54]; however, a detailed binding model is lacking, so it has been difficult to develop structure-based design of integrase inhibitors.”
BackgroundHIV Drug Resistance and the Advent of Integrase Inhibitors
Quashie, P. K., Mésplède, T., & Wainberg, M. A. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0305-1 · Cited by 46
“These drugs contain a halogenated phenyl group that invades the catalytic pocket and displaces the 3′ viral end [30, 34] and three coplanar oxygen atoms that chelate the divalent ions within the catalytic pocket, thus inhibiting the activity of the catalytic DDE triad [4, 6, 26, 35–37].”
BackgroundGarvey, E. P., Schwartz, B. J., Gartland, M. J., Lang, S., Halsey, W. S., Sathe, G. M., Carter, H. L., & Weaver, K. L. (2009) · Biochemistry · doi:10.1021/bi802141y · Cited by 40
Alves, C. N., Martí, S., Castillo, R., Andrés, J., Moliner, V., Tuñón, I., & Silla, E. (2007) · Chemistry - A European Journal · doi:10.1002/chem.200700040 · Cited by 39
Maurin, C., Bailly, F., Buisine, E., Vezin, H., Mbemba, G., Mouscadet, J. F., & Cotelle, P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0408464 · Cited by 40
Ferro, S., Luca, L. D., Barreca, M. L., Iraci, N., Grazia, S. D., Christ, F., Witvrouw, M., Debyser, Z., & Chimirri, A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8009266 · Cited by 40
Jiang, Y., Ng, T. B., Liu, Z., Wang, C., Li, N., Qiao, W., & Liua, F. (2011) · Bioscience Reports · doi:10.1042/bsr20100062 · Cited by 41
Xue, W., Liu, H., & Yao, X. (2011) · Journal of Computational Chemistry · doi:10.1002/jcc.22887 · Cited by 39
Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV
von Kleist, M., Menz, S., & Huisinga, W. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000720 · Cited by 49
“Integration inhibitors affect the integration of viral DNA into the host genome catalytically [42–45].”
BackgroundAuthentic HIV-1 Integrase Inhibitors
Liao, C., Marchand, C., Burke, T. R., Pommier, Y. G., & Nicklaus, M. C. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.199 · Cited by 37
HIV-1 Integrase: From Biology to Chemotherapeutics
Loizidou, E. Z., Nicolaou, C. A., Nicolaides, A. V., & Kostrikis, L. G. (2007) · Current HIV Research · doi:10.2174/157016207781023965 · Cited by 44
“Coordination of the divalent cation at the active site of IN with DKAs is necessary to support the mechanism of action of these inhibitors [112].”
BackgroundSiwe‐Noundou, X., Ndinteh, D. T., Olivier, D. K., Mnkandhla, D., Isaacs, M. L., Muganza, F. M., Mbafor, J. T., van Vuuren, S. F., Patnala, S., Hoppe, H. C., et al. (2018) · South African Journal of Botany · doi:10.1016/j.sajb.2018.08.010 · Cited by 36
“The HIV-1 subtype C integrase (CIN) strand transfer inhibition assay was adapted from previously described method (Grobler et al., 2002).”
MethodDesign and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors
Hu, L., Zhang, S., He, X., Luo, Z., Wang, X., Liu, W., & Qin, X. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.014 · Cited by 37
Alian, A., Griner, S. L., Chiang, V., Tsiang, M., Jones, G., Birkus, G., Geleziunas, R., Leavitt, A. D., & Stroud, R. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811919106 · Cited by 36
“3A), suggesting that the flexible loop can maintain contact with the viral DNA during the proposed IN conformational change between the 3 -processing and strand transfer steps (6, 7, 12, 21), and residues K160 and Q164 come into close proximity with the viral end only during the strand transfer step.”
BackgroundMethodResultInfluentialLee, D. J., & Robinson, W. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5835-5847.2004 · Cited by 36
Chromone and chromanone derivatives as strand transfer inhibitors of HIV-1 integrase
Park, J. H., Lee, S. U., Kim, S. H., Shin, S. Y., Lee, J. Y., Shin, C., Yoo, K. H., & Lee, Y. S. (2008) · Archives of Pharmacal Research · doi:10.1007/s12272-008-1111-z · Cited by 35
4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors
Pace, P., Spieser, S. A. H., & Summa, V. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.056 · Cited by 35
Luca, L. D., Barreca, M. L., Ferro, S., Iraci, N., Michiels, M., Christ, F., Debyser, Z., Witvrouw, M., & Chimirri, A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.089 · Cited by 35
Yan, H., Chiba-Mizutani, T., Nomura, N., Takakura, T., Kitamura, Y., Miura, H. S., Nishizawa, M., Tatsumi, M., Yamamoto, N., & Sugiura, W. (2005) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020501600603 · Cited by 35
“These inhibitors bind to the active site, displace divalent metal ion Mg2+ from the active site and inactivate the catalytic activity of IN (Grobler et al., 2002; Dayam & Neamati, 2003; Goldgur et al., 1999; Johnson et al., 2004).”
BackgroundHIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination
Nishana, M., Nilavar, N. M., Kumari, R., Pandey, M., & Raghavan, S. C. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.237 · Cited by 33
“In the currently accepted model of inhibitor action, the two metal ions bound at the DDE motif are coordinated by the inhibitor.(43) Furthermore, several mutations reported in patients like T66I, S153Y and M154I, that confer resistance to integrase inhibitors are positioned Integrase inhibitors affect RAG activity M N…”
BackgroundLi, X., & Vince, R. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.04.011 · Cited by 35
Barreca, M. L., Luca, L. D., Iraci, N., & Chimirri, A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060323r · Cited by 35
HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede, O., Babu, J., Santo, R. D., McColl, D. J., Weber, J., & Quiñones‐Mateu, M. E. (2008) · PubMed · Cited by 45
Mechanism of HIV antiretroviral drugs progress toward drug resistance
Ammaranond, P., & Sanguansittianan, S. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.01009.x · Cited by 40
Defining the DNA Substrate Binding Sites on HIV-1 Integrase
Dolan, J. R., Chen, A., Weber, I. T., Harrison, R. W., & Leis, J. P. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.083 · Cited by 36
Huang, M., Grant, G. H., & Richards, W. G. (2011) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2011.04.002 · Cited by 34
Switching between raltegravir resistance pathways analyzed by deep sequencing
Mukherjee, R., Jensen, S. T., Male, F., Bittinger, K. L., Hodinka, R. L., Miller, M. D., & Bushman, F. D. (2011) · AIDS · doi:10.1097/qad.0b013e32834b34de · Cited by 32
“For raltegravir (RAL), which inhibits DNA strand transfer by integrase (IN) [3-5], resistance mutations typically arise in the part of the integrase gene encoding the catalytic domain [6-8].”
BackgroundResistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences
Grobler, J. A., & Hazuda, D. J. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.07.006 · Cited by 30
Self-citationSanto, R. D. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796504619 · Cited by 31
“Since a second metal has been observed in an avian sarcoma virus IN crystal structure [3], and because of the two-metal structure for polynucleotide transferases [4, 5], it has been proposed that a second metal (Mg or Mn) can be coordinated between D116 and E152 once HIV-1 IN binds its DNA substrate(s) [6, 7].”
BackgroundLee, D. J., & Robinson, W. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.134-142.2006 · Cited by 30
“L-CA requires one free carboxylic acid for activity (25), while L-731,988 requires both its free carboxylic acid and adjacent carbonyl groups for activity (18).”
BackgroundMugnaini, C., Rajamäki, S., Tintori, C., Corelli, F., Massa, S., Witvrouw, M., Debyser, Z., Veljković, V., & Botta, M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.005 · Cited by 29
Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids
Nair, V., & Okello, M. O. (2015) · Molecules · doi:10.3390/molecules200712623 · Cited by 28
“While many structurally diverse compounds have been reported to be inhibitors of HIV integrase [5,6,23–36], the compounds of one group, the -diketo acids and their congeners and related compounds, are among some of the best known, biologically-validated inhibitors of this key viral enzyme [30,31,37].”
BackgroundGao, K., Wong, S. C., & Bushman, F. D. (2004) · Journal of Virology · doi:10.1128/jvi.78.13.6715-6722.2004 · Cited by 31
“In addition, binding of the diketo-acid inhibitors to the IN active site has been proposed to involve binding two metal atoms as well as protein functional groups (30).”
BackgroundRetroviral Integrase: Then and Now
Andrake, M., & Skalka, A. M. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055043 · Cited by 38
Walker, M. A., Johnson, T., Ma, Z., Banville, J., Rémillard, R., Kim, O., Zhang, Y., Staab, A. J., Wong, H., Torri, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.010 · Cited by 28
Sechi, M., Carta, F., Sannia, L., Dallocchio, R. N., Dessì, A., Al-Safi, R. I., & Neamati, N. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2008.12.010 · Cited by 29
Multivariate QSAR study of 4,5-dihydroxypyrimidine carboxamides as HIV-1 integrase inhibitors
de Melo, E. B., & Ferreira, M. M. C. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.03.001 · Cited by 31
Carayon, K., Leh, H., Henry, E., Simon, F., Mouscadet, J. F., & Deprez, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq087 · Cited by 35
“for resistance mutations to anti-IN compounds (45).”
Ferro, S., Barreca, M. L., Luca, L. D., Rao, A., Monforte, A., Debyser, Z., Witvrouw, M., & Chimirri, A. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200700066 · Cited by 27
Tintori, C., Manetti, F., Veljković, N., Perović, V., Vercammen, J., Hayes, S., Massa, S., Witvrouw, M., Debyser, Z., Veljković, V., et al. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci700078n · Cited by 27
Williams, K. L., Zhang, Y., Shkriabai, N., Karki, R. G., Nicklaus, M. C., Kotrikadze, N., Hess, S. Y., Grice, S. F. J. L., Craigie, R., Pathak, V. K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m413579200 · Cited by 30
Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology
Sun, Y., & Wang, L. (2024) · Pharmaceuticals · doi:10.3390/ph17070887 · Cited by 30
“IN complex [70].”
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors
Zhao, X. Z., Maddali, K., Smith, S. J., Métifiot, M., Johnson, B. C., Marchand, C., Hughes, S. H., Pommier, Y. G., & Burke, T. R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.088 · Cited by 27
Role of integrase inhibitors in the treatment of HIV disease
Palmisano, L. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.1.67 · Cited by 26
The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors
Velthuisen, E. J., Johns, B. A., Temelkoff, D. P., Brown, K. W., & Danehower, S. C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.038 · Cited by 29
Xue, W., Qi, J., Yang, Y., Jin, X., Liu, H., & Yao, X. (2012) · Molecular BioSystems · doi:10.1039/c2mb25114k · Cited by 26
Comparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors
Gupta, P. K., Garg, P., & Roy, N. (2011) · Molecular Diversity · doi:10.1007/s11030-011-9304-7 · Cited by 27
HIV-1 Integrase-DNA Recognition Mechanisms
Kessl, J. J., McKee, C. J., Eidahl, J. O., Shkriabai, N., Katz, A., & Kvaratskhelia, M. (2009) · Viruses · doi:10.3390/v1030713 · Cited by 32
“Strikingly, STIs selectively bind the preformed IN-viral DNA complex rather than free protein [2–4], thus exemplifying the significance of detailed characterization of the functional nucleoprotein complexes.”
BackgroundPolymeric Anti‐HIV Therapeutics
Danial, M., & Klok, H. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201400298 · Cited by 25
Zeng, L., Jiang, X.-H., Sanchez, T. W., Zhang, H.-S., Dayam, R., Neamati, N., & Long, Y. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.008 · Cited by 24
Highly Efficient Preparation of Aryl β-Diketo Acids with tert-Butyl Methyl Oxalate
Jiang, X., Song, L., & Long, Y. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo034903x · Cited by 24
The preclinical discovery and development of dolutegravir for the treatment of HIV
Bailly, F., & Cotelle, P. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1064896 · Cited by 26
“0 Å [20], which was evidenced by us and others in the case of the DKA family [21-24].”
BackgroundHe, H.-Q., Ma, X., Liu, B., Chen, W., Wang, C., & Cheng, S. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00748.x · Cited by 23
Rabaaoui, S., Zouhiri, F., Lançon, A., Leh, H., d'Angelo, J., & Wattel, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-07 · Cited by 23
“DKAs are also thought to bind to the divalent metal ions in the IN active site (23) and compete with target DNA.”
BackgroundFouokeng, Y., Feusso, H. M. F., Teinkela, J. E. M., Siwe‐Noundou, X., Wintjens, R. T., Isaacs, M. L., Hoppe, H. C., Krause, R. W. M., Azébazé, A. G. B., & Vardamides, J. C. (2018) · South African Journal of Botany · doi:10.1016/j.sajb.2018.10.008 · Cited by 25
Sirous, H., Fassihi, A., Brogi, S., Campiani, G., Christ, F., Debyser, Z., Gemma, S., Butini, S., Chemi, G., Grillo, A., et al. (2018) · Medicinal Chemistry · doi:10.2174/1573406415666181219113225 · Cited by 24
Siwe‐Noundou, X., Musyoka, T. M., Moses, V., Ndinteh, D. T., Mnkandhla, D., Hoppe, H. C., Bishop, Ö. T., & Krause, R. W. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-41403-x · Cited by 27
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors
Zhao, X. Z., Maddali, K., Métifiot, M., Smith, S. J., Vu, B. C., Marchand, C., Hughes, S. H., Pommier, Y. G., & Burke, T. R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.047 · Cited by 23
Adhikari, N., Halder, A. K., Mondal, C., & Jha, T. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0897-5 · Cited by 23
“The c-ketone, a-enol, and carboxylic acid in the diketo acid moiety are essential for the inhibitory activity of this series of integrase inhibitors (Grobler et al., 2002).”
Jesumoroti, O. J., Faridoon, F., Mnkandhla, D., Isaacs, M. L., Hoppe, H. C., & Klein, R. (2019) · MedChemComm · doi:10.1039/c8md00328a · Cited by 25
Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
Engelman, K. D., & Engelman, A. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00157 · Cited by 27
Zhao, X. Z., Семенова, Е. А., Liao, C., Nicklaus, M. C., Pommier, Y. G., & Burke, T. R. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.07.064 · Cited by 25
Diketoacid HIV-1 Integrase Inhibitors: An Ab Initio Study
Huang, M., Richards, W. G., & Grant, G. H. (2005) · The Journal of Physical Chemistry A · doi:10.1021/jp045247n · Cited by 22
Developing 2D-QSAR models for naphthyridine derivatives against HIV-1 integrase activity
Zakariazadeh, M., Barzegar, A., Soltani, S., & Aryapour, H. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1305-5 · Cited by 21
“The DDE motif is highly conserved among a superfamily of nucleases and polynucleotidyl-transferases, which includes the retroviral integrases and bacterial transposases coordinated to divalentMg2? cofactors (Grobler et al., 2002; Johns et al., 2009a, b).”
Biological evaluation of imidazolium- and ammonium-based salts as HIV-1 integrase inhibitors
Maddali, K., Kumar, V., Marchand, C., Pommier, Y. G., & Malhotra, S. V. (2011) · MedChemComm · doi:10.1039/c0md00201a · Cited by 22
Resistance to inhibitors of the human immunodeficiency virus type 1 integration
Hazuda, D. J. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70103-3 · Cited by 25
Self-citation
Metadata
- Authors
- Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., & Hazuda, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tufts University (US)
- Corresponding author
- Hazuda, Daria J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-05-07
- Volume
- 99
- Issue
- 10
- Pages
- 6661-6666
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC124459
- OpenAlex
- W2117959947
- Cited by
- 399
- References
- 32
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 4 · 2018: 13 · 2017: 8 · 2016: 12 · 2015: 18 · 2014: 17 · 2013: 18 · 2012: 26
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HIV-1 integrase, strand transfer inhibition, metal-dependent enzyme activity, magnesium cofactor, carboxylate binding, reverse transcription, inhibitor mechanism of action
- MeSH terms
- Binding, Competitive, Humans, Ligands, Magnesium, Manganese, Models, Chemical, Phosphotransferases, Styrenes, Molecular Structure, HIV-1, HIV Long Terminal Repeat, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Streptavidin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.